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Abstract
Introduction: Evaluation of anti-inflammatory action of Codelac® Broncho with Thymus Serpyllum (elixir) in com-
parison with Fenspiride was carried out on the model of acute carrageenan inflammation of the paws in rats.
Materials and methods: Edema was caused by subplantar injection of 0.1 ml of 1% λ- carrageenan gel into the hind 
paw. The severity of edema was assessed by using 37140 plethysmometer (UGO BASILE, Italy). The measurements 
were performed before edema induction and 1, 2, 4, 12, 24, 48, 72, 96 and 120 hours afterwards. Anti-inflammatory 
activity of the drugs was also evaluated based on the analysis of rats’ blood, C-reactive protein concentration and his-
tological examination results.
Results and discussion: A decrease in the paw volume increment was revealed in the group with the studied drug in 
comparison with the group with the carrageenan edema model (control) 4, 12, 24 hours after injection of carrageenan 
(p<0.05). As a result of plethysmometry, a more pronounced anti-inflammatory effect of the studied drug than that of 
Fenspiride was revealed. There was a significant decrease in the levels of leukocytes (p<0.05), lymphocytes (p<0.05), 
monocytes (p<0.05) and neutrophils (p<0.05) in the group with the studied drug compared to those the the control 
48 hours after the initiation of edema, while in the group with Fenspiride, there was only a decrease in the levels of 
leukocytes (p<0.05) and lymphocytes (p<0.05). There were no differences in the concentration of C-reactive protein 
between the groups.
Conclusion: The obtained data indicate a more pronounced anti-inflammatory activity of Codelac® Broncho with 
Thymus Serpyllum in comparison with Fenspiride, on the model of acute carrageenan inflammation of the paw in rats.
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Introduction
Acute inflammation is characterized by rapid development 
of local inflammatory reaction in response to phlogogen 
and systemic reaction in the acute-phase response (Eni-
keev et al. 2017). Inflammation is the main adaptive 
process underlying many pathological conditions (flu, 
asthma, pneumonia, arthritis, etc.). At the heart of the in-
flammatory response is a complex of cellular and humoral 
factors produced in response to damage and aimed at its 
relief (Demyanov and Kotov 2003, Liang et al. 2015).
At the heart of the exudation phase is the reaction of 
the microcirculatory bed in the form of malperfusion at 
the site of injury, increased permeability of the vascular 
wall, exudation of plasma and emigration of blood cells 
from the vascular lumen to the surrounding tissues and 
phagocytosis. In the initial stages of the exudative phase, 
in response to perturbed vascular endothelium and dis-
rupted platelets, there is release of endothelins, catecho-
lamines, thromboxane A2 and leukotrienes, the vasocon-
strictor tone reflexively increases, and at the site of injury 
there develops a short-term local spasm of arterioles last-
ing from a few seconds to a few minutes (Poryadin 2014).
As a result of the activating effect of IL-1, IL-8 and other 
pro-inflammatory mediators on neutrophils, there is an in-
crease in the synthesis and isolation of lysosomal enzymes 
and leukotrienes, activation of phagocytosis, as well as a res-
piratory explosion with neutrophil degranulation. Under the 
influence of neutrophils, there is a change in the cell popu-
lation in the focus of inflammation with the accumulation of 
macrophages there (Serebryannikov and Seminsky 2014).
Fenspiride hydrochloride has a complex anti-inflam-
matory effect on the mucous membrane of respiratory 
tract (RT) in acute respiratory infection (ARI). Acting on 
the metabolism of arachidonic acid, Fenspiride reduces 
the formation of prostaglandins and leukotrienes, being 
an antagonist of H1-histamine receptors and α1-receptors, 
reduces bronchial hyperreactivity, and prevents bron-
choconstriction (Erdes 2004, Ovcharenko and Glukhare-
va 2009, Sokolov 2003, Tatochenko 2007).
In addition to ambroxol, which has a mucolytic and 
expectorant effect, the composition of Codelac® Broncho 
with Thymus Serpyllum (elixir) includes sodium glycyr-
rhizinate and thyme extract, each of which has an anti-in-
flammatory effect (Bernela et al. 2016, Marianecci et al. 
2014, Qadir et al. 2016). Their combined application is 
assumed to lead to synergy, as a result of which Codelac® 
Broncho with Thymus Serpyllum (elixir) is able to have a 
pronounced anti-inflammatory effect.
It should be noted that traditional antitussives have no 
anti-inflammatory activity. The combination of mucolyt-
ic, expectorant and anti-inflammatory effects of Codelac® 
Broncho with Thymus Serpyllum (elixir) should lead to a 
more pronounced therapeutic efficacy in the treatment of 
bronchitis, COPD, pneumonia, and bronchiectasis.
In connection with the above, it was relevant to study 
the anti-inflammatory activity of the combined drug 
Codelac® Broncho with Thymus Serpyllum (elixir), con-
taining two components with anti-inflammatory action (in 
particular, of plant origin), in comparison with the drug 
containing anti-inflammatory monocomponent – Fenspir-
ide (syrup), on the model of acute carrageenan inflamma-
tion of the paw in rats.
Objective: to study the anti-inflammatory activity 
of Codelac® Broncho with Thymus Serpyllum (elixir), 
in comparison with Fenspiride (syrup), on the model of 
acute carrageenan inflammation of the paw in rats.
Materials and methods
The experiments were performed in Wistar rats weig-
hing 225–275 g, without any external signs of disease, 
and which had passed through quarantine. The ethical 
principles of handling laboratory animals were observed 
in accordance with the European Convention for the Pro-
tection of Vertebrate Animals Used for Experimental and 
Other Scientific Purposes, CETS No. 123. The experiment 
included the following groups: the first (n=10) – control 
(model of carrageenan edema), the second (n=10) – with 
the administration of Codelac® Broncho with Thymus 
Serpyllum (elixir) against the background of the simulated 
carrageenan edema, the third (n=10) – with the adminis-
tration of Fenspiride against the background of the simu-
lated carrageenan edema. Codelac® Broncho with Thymus 
Serpyllum (elixir) (OTCPharm PJSC) was injected to rats 
intragastrically in a volume of 0.17 ml 4 times a day. Fen-
spiride (Erispirus syrup, 2 mg/ml, SANDOZ) was injected 
intragastrically in a volume of 0.29 ml 4 times a day.
Edema was caused by subplantar injection (under 
the plantar aponeurosis) of 0.1 ml of 1% λ-carrageenan 
aqueous gel (SIGMA 22049 λ-Carrageenan plant muco-
polysaccharide, SIGMA-ALDRICH), which had been 
prepared before the injection (Mironov 2012), into the 
right hind paw of the rat. The severity of edema was as-
sessed by measuring the volume of animals’ paws using 
37140-plethysmometer (UGO BASILE, Italy). Measure-
ments were performed before edema induction (initial 
volume) and 1, 2, 4, 12, 24, 48, 72, 96 and 120 hours after 
subplantar injection of carrageenan.
The anti-inflammatory activity of the drugs was eval-
uated by a decrease in the paw volume increment, ex-
pressed as a percentage of the initial volume, compared 
to the control group. The volume of paws of the animal 
before the injection of carrageenan was taken as the initial 
volume (100%). A share (%) of paw volume increment = 
[(volume after injection of carrageenan at a certain mo-
ment – initial volume) / initial volume] × 100.
For cytological analysis, blood was taken from the rats 
prior to and 4 h, 12 h, 24 h, 48 h, and 120 hours after the 
injection of carrageenan. The concentration of C-reactive 
protein was determined before and 4 hours and 24 hours 
after the injection of carrageenan.
The histological picture was described according to the 
data obtained in one animal from each group 4 and 24 
hours after the inflammation induction.
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For all the data obtained, descriptive statistics were 
used, and the data were checked for normal distribution. 
A distribution type was determined by using the Shap-
iro-Wilk criterion. In case of normal distribution, the 
mean value (M) and standard error of the mean (SEM) 
were calculated. Between-group differences were analyz-
ed by parametric (t-Student criterion) or non-parametric 
(Mann-Whitney test) methods, depending on a type of 
distribution. Differences were determined at a 0.05 sig-
nificance level. Statistical analyses were performed using 
STATISTICA 10.0 software.
Results and discussion
Injection of 0.1 ml of 1% aqueous gel of λ- carrageenan 
under plantar aponeurosis led to the development of a 
pronounced inflammatory reaction, with edema reaching 
the greatest degree of severity about 3 hours after the in-
jection. A general view of the hind paws of rats 3 hours af-
ter the initiation of carrageenan edema in the groups with 
correction by the studied drug and the comparison drug is 
shown in Figure 1.
Table 1 presents the results obtained when calculat-
ing the volume of edema at different time points in the 
study groups.
In case of injecting Codelac® Broncho with Thymus 
Serpyllum, there was a significant decrease in the paw 
volume increment compared to that in the control group, 
starting with 4 hours after the initiation of edema, by 
42.4% (p<0.05), while in the group with the injection 
of the comparison drug, there were no significant dif-
ferences observed from the values of the control group. 
In the group with the injection Fenspiride, 8 hours after 
the induction of edema, there was observed a significant 
decrease in the paw volume increments in comparison 
with the control group – by 40.6% (p<0.05), while in the 
group with the injection of the studied drug there were 
not significant differences observed from the control. In 
the group with Codelac® Broncho with Thymus Serpyl-
lum, 12 and 24 hours after the injection of carrageenan, 
there was a decrease in the increase in the paw volume 
increments, which indicated the anti-inflammatory activ-
ity of the studied drug on the model of acute carrageenan 
inflammation of the paw in rats (Fig. 2). Starting from 72 
hours after the initiation of edema and further, there was 
normalization of indicators in all groups.
The analysis of rats’ blood revealed a significant de-
crease in the levels of leukocytes (p<0.05), lymphocytes 
Table 1. Effects of Codelac® Broncho with Thymus Serpyllum 
(elixir) and Fenspiride (syrup) on the Change of Paw Volume 
Increment with the Simulated Carrageenan Edema (m±SEM; 
n=10), % of initial volume.
Time Fenspiride 
(syrup)
Codelac® Broncho with 
Thymus Serpyllum (elixir)
Control
1 h 7.54 ± 1.39 6.87 ± 1.28 9.59 ± 2.03
2 h 13.48 ± 1.39 9.84 ± 1.11 14.12 ± 2.31
4 h 11.61 ± 1.71 9.48 ± 1.68* 16.46 ± 2.02
8 h 10.28 ± 1.10* 12.92 ± 6.01 17.32 ± 1.52
12 h 10.51 ± 1.95* 9.54 ± 2.01* 18.07 ± 2.20
24 h 2.07 ± 1.04* 0.69 ± 1.23* 9.50 ± 2.37
48 h 1.18 ± 0.59 0.46 ± 0.90 2.72 ± 1.47
72 h 0 0 0
96 h 0 0 0
120 h 0 0 0
Note: * - p<0.05 compared to the control group.
A B
Figure 1. General view of the hind paw 3 hours after the initiation of carrageenan edema with the injection of: A – Codelac® Bron-
cho with Thymus Serpyllum (elixir), B – Fenspiride (syrup).
Figure 2. The influence of Codelac® Broncho with Thymus Serpyl-
lum (elixir) and Fenspiride (syrup) on change in paw volume incre-
ments on the model of acute carrageenan inflammation of the paw.
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(p<0.05), monocytes (p<0.05) and neutrophils (p<0.05) 
in comparison with those in the control group 48 hours af-
ter the initiation of edema with the correction by Codelac® 
Broncho with Thymus Serpyllum (elixir), while in the 
group with the correction by Fenspiride (syrup), there 
was only a significant decrease in the levels of leukocytes 
(p<0.05) and lymphocytes (p<0.05) (Table 2). The data 
obtained indicate a more pronounced anti-inflammatory 
activity of Codelac® Broncho with Thymus Serpyllum 
(elixir) in comparison with Fenspiride (syrup).
There were no significant differences in the concentra-
tion of C-reactive protein in the groups treated with the 
studied drug and the comparison drug (Table 3).
Table 2. The Results of the Analysis of Blood in Case of Injecting Codelac® Broncho with Thymus Serpyllum (elixir) and Fenspir-
ide (syrup) Against the Background of Acute Carrageenan Inflammation of the Paw in Rats (M ± SEM).
Indicators Initial 4 hours after initiation of edema
Control Codelac® Fenspiride Control Codelac® Fenspiride
leukocytes *10х9/L 7.30±0.65 7.44±0.46 7.66±0.29 7.23±0.69 9.43±0.82 9.95±1.03
lymphocytes *10х9/L 3.29±0.38 3.44±0.26 3.66±0.29 3.49±0.43 4.38±0.39 4.53±0.40
monocytes *10х9/L 0.43±0.06 0.50±0.07 0.35±0.03 0.38±0.09 0.30±0.03 0.43±0.07
basophils *10х9/L 0.03±0.02 0.04±0.02 0.05±0.02 0.04±0.01 0.03±0.02 0.05±0.02
eosinophils *10х9/L 0.18±0.03 0.13±0.02 0.21±0.01 0.18±0.02 0.18±0.02 0.23±0.03
neutrophils *10х9/L 3.39±0.42 3.34±0.38 3.39±0.21 3.15±0.51 4.55±0.43 4.73±0.54
neutrophils, % 46.44±3.75 44.54±3.04 44.52±3.12 43.2±2.1 48.10±0.90 47.26±0.78
lymphocytes, % 45.14±3.43 46.59±3.09 47.50±2.95 48.5±1.5 46.35±0.40 45.89±0.93
eosinophils, % 2.36±0.34 1.68±0.17 2.82±0.24 2.48±0.26 1.98±0.30 2.24±0.28
basophils, % 0.32±0.22 0.46±0.23 0.62±0.24 0.50±0.10 0.28±0.20 0.41±0.17
monocytes, % 5.74±0.67 6.74±0.84 4.54±0.34 11.1±2.3 3.29±0.36 4.20±0.48
Indicators 12 hours after initiation of edema 24 hours after initiation of edema
Control Codelac® Fenspiride Control Codelac® Fenspiride
leukocytes *10х9/L 7.18±0.69 7.20±0.68 8.28±0.85 11.38±1.42 8.96±0.78 9.10±0.74
lymphocytes *10х9/L 2.98±0.29 3.33±0.29 3.75±0.44 4.98±0.69 4.14±0.46 3.78±0.33
monocytes *10х9/L 0.45±0.08 0.40±0.05 0.55±0.11 0.69±0.14 0.55±0.07 0.51±0.07
basophils *10х9/L 0.00±0.00 0.03±0.02 0.00±0.00 0.05±0.02 0.03±0.02 0.03±0.02
eosinophils *10х9/L 0.13±0.02 0.18±0.02 0.20±0.03 0.23±0.05 0.16±0.02 0.20±0.03
neutrophils *10х9/L 3.63±0.40 3.28±0.38 3.78±0.29 5.44±0.59 4.09±0.43 4.59±0.35
neutrophils, % 50.57±2.18 44.95±1.54 46.73±1.91 48.36±1.84 45.81±2.73 50.72±1.39
lymphocytes, % 41.74±2.23 46.45±0.76 44.81±0.93 43.44±1.67 45.96±2.36 41.36±1.52
eosinophils, % 1.76±0.17 2.67±0.44 2.36±0.13 1.95±0.29 1.85±0.20 2.14±0.17
basophils, % 0.00±0.00 0.29±0.21 0.00±0.00 0.42±0.18 0.24±0.16 0.22±0.14
monocytes, % 5.93±0.65 5.65±0.69 6.09±0.99 5.83±0.50 6.14±0.65 5.56±0.62
Indicators 48 hours after initiation of edema 120 hours after initiation of edema
Control Codelac® Fenspiride Control Codelac® Fenspiride
leukocytes *10х9/L 21.04±1.20 14.75±1.32* 16.28±0.93* 17.74±1.58 14.61±1.75 13.20±1.43
lymphocytes *10х9/L 9.64±0.50 6.89±0.74* 6.76±0.40* 8.71±1.13 6.81±1.00 6.36±0.68
monocytes *10х9/L 0.91±0.10 0.58±0.05* 0.80±0.09 0.74±0.07 0.75±0.15 0.61±0.09
basophils *10х9/L 0.08±0.02 0.06±0.02 0.05±0.02 0.10±0.02 0.05±0.03 0.08±0.03
eosinophils *10х9/L 0.39±0.02 0.30±0.04 0.35±0.04 0.38±0.05 0.31±0.04 0.28±0.04
neutrophils *10х9/L 10.03±1.21 6.93±0.64* 8.31±0.60 7.81±0.80 6.69±0.72 5.88±0.68
neutrophils, % 46.65±3.29 47.21±2.12 50.94±1.60 44.59±2.99 46.58±2.34 44.31±1.04
lymphocytes, % 46.63±2.95 46.20±2.14 41.69±1.45 48.38±2.80 45.95±2.17 48.36±1.21
eosinophils, % 1.88±0.14 2.04±0.18 2.15±0.20 2.10±0.18 2.15±0.18 2.12±0.22
basophils, % 0.38±0.09 0.40±0.12 0.29±0.11 0.58±0.10 0.29±0.16 0.53±0.16
monocytes, % 4.46±0.50 4.15±0.55 4.93±0.48 4.35±0.51 5.03±0.64 4.67±0.49
Note: * - p<0.05 compared to the control group.
Table 3. The C-reactive Protein Concentration When Using 
Codelac® Broncho with Thymus Serpyllum (elixir) and Fenspir-
ide (syrup) on the Model of Acute Carrageenan Inflammation of 
the Paw in Rats (M ± SEM).
Groups Time of blood sampling (after 
injection of carrageenan)
Before 
injection
4 h 24 h
Control 0.13±0.03 0.15±0.01 0.17±0.02
Codelac® Broncho with 
Thymus Serpyllum (elixir)
0.15±0.02 0.16±0.01 0.18±0.02
Fenspiride (syrup) 0.17±0.03 0.15±0.01 0.18±0.03
Research Results in Pharmacology 5(1): 45–52 49
The following histological picture was observed in 
the control group 4 hours after initiation of edema. The 
epidermis of the plantar surface of the foot had a usual 
structure, without abnormalities. The corneal layer was 
well-defined. The skin itself consisted of the papillary and 
reticular layers of the conventional structure. The hypoder-
mis consisted of mainly subcutaneous fat tissue with signs 
of moderate inflammation, vascular and capillary plethora. 
The underlying muscular tissue had signs of acute purulent 
inflammation in the form of purulent (fibrinous-purulent) 
deposits on muscular perimysium and moderate purulent 
infiltration within the muscle (Figs 3, 4).
In the group with the treatment of edema by Codelac® 
Broncho with Thymus Serpyllum (elixir), 4 hours after 
initiation of carrageenan edema, the epidermis plantar 
surface of the foot was of the usual structure, without ab-
normalities. The corneal layer was well defined. The skin 
itself consisted of the papillary and reticular layers of the 
conventional structure. Hypodermis consisted of mainly 
subcutaneous fat tissue with signs of mild inflammation. 
The underlying muscular tissue had signs of acute mild 
inflammation, with severe inflammation in the form of 
purulent (fibrinous-purulent) deposits on muscular perim-
isium as viewed from the hypodermis (Fig. 5).
In the group with the treatment of edema by Fenspiri-
de, 4 hours after initiation of carrageenan edema, the ep-
idermis of the plantar surface of the foot was of the usual 
structure, without abnormalities. The corneal layer was 
well-defined. The skin itself consisted of the papillary and 
reticular layers of the conventional structure. The hypo-
dermis consisted of mainly subcutaneous fat tissue with 
signs of severe inflammation. The underlying muscular 
tissue had no signs of acute inflammation (Fig. 6).
In the control group 24 hours after the initiation of ede-
ma, the histological examination revealed the following: 
the dermis and epidermis of the plantar surface of the foot 
were of the usual structure, without abnormalities. The 
corneal layer was well-defined. The hypodermis had signs 
of an acute purulent inflammation, microabscess forma-
tion, vascular and capillary plethora, and fibrinous throm-
bi in a number of venous lumens. The underlying mus-
cular tissue had a general purulent inflammation (Fig. 7).
In the group with the treatment of edema by Codelac® 
Broncho with Thymus Serpyllum (elixir), 24 h after initi-
Figure 3. Histological picture 4 hours after initiation of carrageenan edema in the control group. Stained with haematoxylin 
and eosin. ×40.
A B
A B
Figure 4. Histological picture 4 hours after initiation of carrageenan edema in the control group. Stained with haematoxylin 
and eosin. ×200.
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Figure 5. Histological picture 4 hours after initiation of carrageenan edema in the group with the treatment by Codelac® Broncho 
with Thymus Serpyllum (elixir). Stained with haematoxylin and eosin. ×100 (A), ×200 (B).
A B
Figure 6. Histological picture 4 hours after initiation of car-
rageenan edema in group with the treatment by Fenspiride. 
Stained with haematoxylin and eosin. ×200.
Figure 7. Histological picture 24 hours after initiation of car-
rageenan edema in the group with the treatment by Fenspiride. 
Stained with haematoxylin and eosin. ×100.
ation of carrageenan edema, the dermis and epidermis of 
the plantar surface of the foot were of normal structure, 
without abnormalities. The corneal layer was well-de-
fined. The hypodermis had signs of a mild inflammation. 
The underlying muscular tissue had no signs of acute in-
flammation (Fig. 8).
In the group with the treatment of edema by Fenspiri-
de, 24 h after initiation of carrageenan edema, the dermis 
and epidermis of the plantar surface of the foot were of 
normal structure, without abnormalities. The corneal lay-
er waswell-defined. The hypodermis had signs of an acute 
diffuse local purulent inflammation with microabscess 
formation. There were fibrinous thrombi in the veins. The 
underlying muscular tissue had signs of incipient inflam-
mation (Fig. 9).
Thus, the results of a comprehensive assessment, in-
cluding the data of plethysmometric study, blood analy-
sis and histological study, showed the presence of a pro-
nounced anti-inflammatory effect of Codelac® Broncho 
with Thymus Serpyllum (elixir), exceeding the effects of 
the comparison drug Fenspiride (syrup) on the model of 
acute inflammation of the paw in rats.
In most cases, the etiological factor of inflammation 
of the mucous membrane of the respiratory system is vi-
ruses and viral-bacterial associations. It is important to 
effectively influence local protection factors in the ear-
ly stages of the disease to prevent desease progression, 
spread and complications. Considereing the pathogene-
sis of the infectious process, along with etiotropic agents 
in the treatment of acute respiratory infections (ARI), it 
is important to use drugs that quickly reduce edema and 
hyperemia of the mucous membrane, eliminate cough, 
adjust sputum production and improve its discharge, 
prevent the development of hyperreactivity and irrevers-
ible changes in the mucous membrane of the respiratory 
tract (RT). RT has abundant innervation of C-fibers and 
Aδ-fibers of sensory neurons located in the jugular, no-
dose, trigeminal ganglia, as well as in the ganglia of the 
posterior roots of the spinal cord. Stimulation of these 
fibers leads to the release of inflammatory neuropeptides 
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into the respiratory tract, such as substance P, CGRP and 
neurokinin A, which in turn induce bronchospasm, vaso-
dilation, immune cell recruitment and modulation of the 
inflammatory response. All this is manifested in the form 
of cough, an increased mucus production, rapid breath-
ing, aimed at the elimination of the irritant. Long-term 
inflammation due to constant exposure to the irritant, or 
diseases such as cystic fibrosis, eventually lead to chronic 
cough, COPD, asthma and reactive airway dysfunction 
syndrome (Bautista et al. 2013).
Anti-inflammatory effect of Codelac® Broncho with 
Thymus Serpyllum is determined by the action of glyc-
erate (glycyrrhizic acid and its salts). Glycyrrhizic acid 
(GA), undergoing metabolic transformations in the body, 
has a corticosteroid-like effect, resulted from its moder-
ate stimulation of the adrenal cortex. GA and its agly-
cone enhance the effect of exogenous hormones of the 
adrenal cortex, inhibit oxidative phosphorylation and 
biosynthesis of sulfated mucopolysaccharides which 
reduce the activity of phospholipase A2, increase the 
glutamine transaminase activity. GA and its derivatives 
affect the cascade of arachidonic acid in the same way as 
NSAIDs, inhibiting the biosynthesis of prostaglandins. 
Thus, ammonium glycyrrhizinate suppresses the forma-
tion of prostaglandins E2 and F2ά in lungs and kidneys 
of mice. GA and glycyrrhetic acid inhibit the synthesis 
of prostoglandin E2 by activated macrophages; a simi-
lar process occurs in the culture of exudative cells. An-
ti-inflammatory properties of GA are due to its effect on 
inflammatory mediators – neutrophils. In particular, GA 
inhibits the release of singlet oxygen, hydrogen perox-
ide and OH ions in dose-dependent form by neutrophils 
(Tolstikov et al. 1997).
Extract of creeping thyme (Thytnus) contains a com-
plex of biologically active substances with expectorant, 
anti-inflammatory, and antimicrobial effects. Due to the 
thyme having thymol and carvacrol, thyme-based prepa-
rations are effective in inflammatory processes caused by 
microflora resistant to antibiotics. Thyme preparations are 
used to treat inflammatory diseases of the oral cavity and 
pharynx, laryngitis, tracheitis, bronchitis and broncho-
pneumonia (Sokolov 2000).
Conclusion
The study revealed the following:
– there was a significant decrease in paw volume incre-
ment in the group with the treatment of carrageenan 
edema by Codelac® Broncho with Thymus Serpyllum 
(elixir) in comparison with the group with the model of 
carrageenan edema (control) 4, 12, 24 hours after the 
injection of carragenine (p<0.05). The plethysmomet-
ric study revealed a more pronounced anti-inflammato-
ry effect of the studied drug than the comparison drug 
Fenspiride (syrup), within the specified time frame;
– there was a significant decrease in the levels of leu-
kocytes (p<0.05), lymphocytes (p<0.05), monocytes 
(p<0.05) and neutrophils (p<0.05) compared to those 
in the control group 48 hours after the initiation of 
edema when administering Codelac® Broncho with 
Thymus Serpyllum (elixir), while in the group with the 
injection of Fenspiride (syrup) there was only a signif-
icant decrease in the levels of leukocytes (p<0.05) and 
lymphocytes (p<0.05);
– in the groups with the injection of the studied drug 
and the comparison drug, there were no significant dif-
ferences in the concentration of C-reactive protein in 
comparison with the control group;
– the histological study confirmed the presence of a more 
pronounced anti-inflammatory activity of Codelac® 
Broncho with Thymus Serpyllum (elixir), surpassing 
the effects of Fenspiride (syrup) on the model of acute 
carrageenan inflammation of the paw in rats 4 and 24 
hours after initiation of edema.
Figure 8. Histological picture 24 hours after initiation of car-
rageenan edema in the group with the treatment by Codelac® 
Broncho with Thymus Serpyllum (elixir). Stained with haema-
toxylin and eosin. ×100.
Figure 9. Histological picture in 24 hours after initiation of 
carrageenan edema in the group with correction by Fenspiride. 
Stained with haematoxylin and eosin. ×100.
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